Goldman Sachs Upgrades Quanterix to Neutral, Announces $40 Price Target

Goldman Sachs analyst Matthew Sykes upgrades Quanterix (NASDAQ:QTRX) from Sell to Neutral and announces $40 price target.

byBenzinga Newsdesk

March 2, 2022

1 minute read

Goldman Sachs analyst Matthew Sykes upgrades Quanterix (NASDAQ:QTRX) from Sell to Neutral and announces $40 price target.

Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $750

By Benzinga Newsdesk

Today, 11:34 PM

Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:IDXX) with a Overweight and raises the price target from $616 to $750.

IDXX

Why Is Dogecoin Crashing Again Today?

By Shivdeep Dhaliwal

Today, 11:34 PM

Dogecoin (CRYPTO: DOGE) crashed 19.99% to $0.24 in the early hours of Wednesday. What’s Moving? The meme cryptocurrency was down 13.07% over a seven-day trailing period at press time.

COIN

Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $105

By Benzinga Newsdesk

Today, 11:34 PM

Credit Suisse analyst Tiago Fauth maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and raises the price target from $100 to $105.

BMRN

Bolt Biotherapeutics To Present Updates For Three Preclinical Immuno-Oncology Pipeline Programs At AACR Annual Meeting 2022 Apr. 12 And 13

By Bill Haddad

Today, 11:34 PM

Bolt Biotherapeutics (NASDAQ:BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology therapeutics that combine the targeting precision of antibodies with the power of both the innate and

BOLT

Goldman Sachs Upgrades Quanterix to Neutral, Announces $40 Price Target

Related Posts

Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $750

Why Is Dogecoin Crashing Again Today?

Credit Suisse Maintains Outperform on Biomarin Pharmaceutical, Raises Price Target to $105

Bolt Biotherapeutics To Present Updates For Three Preclinical Immuno-Oncology Pipeline Programs At AACR Annual Meeting 2022 Apr. 12 And 13